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Abstract
Background: Treatment failure during venom immunotherapy (VIT) may be associated with a variety of risk factors.
Objective: Our aim was to evaluate the association of baseline serum tryptase concentration (BTC) and of other parameters
with the frequency of VIT failure during the maintenance phase.
Methods: In this observational prospective multicenter study, we followed 357 patients with established honey bee or
vespid venom allergy after the maintenance dose of VIT had been reached. In all patients, VIT effectiveness was either
verified by sting challenge (n = 154) or patient self-reporting of the outcome of a field sting (n = 203). Data were collected on
BTC, age, gender, preventive use of anti-allergic drugs (oral antihistamines and/or corticosteroids) right after a field sting,
venom dose, antihypertensive medication, type of venom, side effects during VIT, severity of index sting reaction preceding
VIT, and duration of VIT. Relative rates were calculated with generalized additive models.
Results: 22 patients (6.2%) developed generalized symptoms during sting challenge or after a field sting. A strong
association between the frequency of VIT failure and BTC could be excluded. Due to wide confidence bands, however,
weaker effects (odds ratios ,3) of BTC were still possible, and were also suggested by a selective analysis of patients who
had a sting challenge. The most important factor associated with VIT failure was a honey bee venom allergy. Preventive use
of anti-allergic drugs may be associated with a higher protection rate.
Interpretation: It is unlikely that an elevated BTC has a strong negative effect on the rate of treatment failures. The
magnitude of the latter, however, may depend on the method of effectiveness assessment. Failure rate is higher in patients
suffering from bee venom allergy.
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Introduction
About 10% of patients suffering from Hymenoptera venom
allergy present with an elevated baseline tryptase concentration
(BTC .11.4 mg/L) [1]. BTC is believed to represent the
individual mast cell burden of a patient. To a large part, increased
concentrations result from systemic mastocytosis or monoclonal
mast cell activation syndrome [2]. Elevated BTC may also be
found in patients with other mast cell diseases like chronic urticaria
[3], uremic pruritus [4] or in patients with myeloid malignancies
[2]. Apart from mastocytosis, mast cell number and life span may
be chronically elevated in unselected allergic patients [5].
In allergic patients, it is unequivocally established that an
increased BTC is a dominating risk factor for severe systemic
reactions after a field sting by wasps or honey bees [1,6]. During
venom immunotherapy (VIT), the importance of BTC for severe
side effects is less clear. A strong, independent association could
only be shown in patients treated with wasp venom during the
build-up phase [7]. After VIT, the importance of BTC for
treatment failure is also controversial. Some consider BTC as an
important predictor of the chance of VIT failure, and of the risk of
relapse if VIT is stopped [8], whereas others were unable to find a
strong association between a high BTC and the effectiveness of
VIT [9]. For patients with systemic mastocytosis, in whom a
particularly high BTC (.20.0 mg/l) is an important diagnostic
criterion, some authors concluded that VIT may reduce the
frequency of subsequent systemic allergic reactions to a clearly
lesser extent than in allergic patients not presenting with clonal
mast cell diseases [10,11]. Others, however, claim that VIT is safe
and effective in patients with mastocytosis [12].
It was the aim of the present prospective international
multicenter study to determine the importance of BTC and of
other suspected risk factors for VIT failure during the mainte-
nance phase of VIT. Furthermore, since the precise magnitude of
the treatment effect is still unknown, the present study also wanted
to examine the rate of VIT failure in an unselected patient cohort
suffering from Hymenoptera venom allergy. The first and the
second part of that study, which examined risk factors for severe
anaphylactic reactions after a field sting which preceded VIT, or
for severe side effects during the build-up phase of VIT, were
published recently [1,7].
Methods
Study Design
The Tryptase in Hymenoptera Venom Allergy (TIHVA) study
of the Interest Group on Insect Venom Hypersensitivity of the
European Academy of Allergology and Clinical Immunology
(EAACI) is a prospective observational cohort study, which was
performed in 14 European clinics specialized on the diagnosis and
treatment of allergic diseases. In patients suffering from Hyme-
noptera venom allergy, we had evaluated risk factors for severe
systemic reactions after a field sting (before VIT) and during the
build-up phase of VIT (part I and II of the study) [1,7]. In part III
of the study, we now present data on the therapeutic effectiveness
of VIT in a patient subgroup examined during the maintenance
phase of VIT. Design of the TIHVA study, patient enrolment,
diagnostic procedures, laboratory tests, data accuracy and
characteristics of the core population have been presented in
detail in previous publications [1,7].
For the present study, we analyzed those patients in whom the
effectiveness of VIT could be assessed (either by in-hospital sting
challenge or by patient-reported reactions to accidental field
stings). Patients were excluded if they had not undergone a sting
challenge or if they had not sustained a sting by the culprit insect
during follow up. Patients who had sustained a field sting and who
were uncertain about the species of the stinging insect, or in whom
symptoms were equivocal, or whose history could not precisely be
obtained, were also excluded from the analysis. We also did not
incorporate patients into the study who had had a field sting by the
culprit insect during the build-up phase of VIT. Patients, who
were allergic to both bee and wasp venom, could not be evaluated
in the present study. Absence of a double allergy was a prerequisite
for being enrolled in the core population of this long-term project
[1].
Venom Immunotherapy
For the majority of subjects, the maintenance dose was 100 mg.
In selected high risk patients (bee keepers or other patients with a
particularly high risk of insect exposure) and in some of the
patients who had experienced severe side effects during the
maintenance phase, a maintenance dose of 200 mg was used.
Indications for using a higher venom dose were not specified.
Effectiveness of Hymenoptera Venom Immunotherapy
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The method and date of effectiveness assessment (in-hospital
sting challenge or patient-reported reactions to accidental field
stings) was left to the discretion of the treating study centre. Sting
challenges were performed according to European guidelines [13]
which also indicate specific contraindications such as unstable
internal diseases (asthma, cardiac disease), or pregnancy. Emer-
gency treatment followed specific guidelines. Even in the absence
of hemodynamic symptoms, all cases developing cutaneous
symptoms during sting challenge were treated immediately.
Patient Management during the Maintenance Phase of
VIT
At regular time intervals, all patients were seen as outpatients
for therapy continuation (3 to 5 years after the end of the build-up
phase). Patients were asked for symptoms which might have
occurred after a field sting by the culprit insect. For treatment of
symptoms in the event of being stung by the culprit insect, all
patients had been provided with an emergency kit including an
H1-blocking high-dose antihistamine, a corticosteroid and an
adrenaline auto-injector. In addition, patients with airway
symptoms received a bronchodilator. Patients had been advised
to immediately take antihistamines and corticosteroids after a field
sting, and before the onset of symptoms [14,15]; adrenaline auto-
injectors should only be used in case of a systemic reaction.
In addition to emergency treatments, preventative measures
were provided including education (avoidance advice) on how to
avoid bee and/or wasp stings, and on how to recognise the early
symptoms of anaphylaxis.
Baseline and Test Variables
Besides age (at the time of the sting challenge, or of the first
eventful or the last uneventful field sting) and gender, we recorded
preventive use of an emergency medication after a field sting (use
of oral antihistamines or of antihistamines and corticosteroids
before the appearance of clinical symptoms), venom dose during
maintenance therapy, the type of antihypertensive medication,
which was taken during the sting challenge or field sting and the
type of venom used for therapy. We also recorded the frequency of
systemic allergic reactions during the build-up or maintenance
phase of VIT, and the severity grade (according to Ring [16]) of
the most severe sting reaction prior to VIT. We furthermore,
collected information on the time interval between the end of the
build-up phase of VIT and the day of the sting challenge, or of the
first eventful or the last uneventful field sting. We also documented
whether effectiveness had been assessed by sting challenge or
patient-reported reactions. When taking the patient’s history,
particular attention was paid to the order of events (e.g.,
medication before or after the onset of symptoms). Test variable
was the baseline serum tryptase concentration (BTC).
End point of the present analysis was an objective systemic
reaction during an in-hospital sting challenge or after a field sting
by the culprit insect. Objective systemic reactions included itching
and urticaria (but not itching alone), flush and hemodynamic
shock. At least one of these symptoms must have occurred to
diagnose a systemic reaction. Three conditions were defined as
being compatible with signs of a hemodynamic shock: a) heart
rate.systolic blood pressure when recorded during sting chal-
lenge, b) heart rate.systolic blood pressure registered by an
emergency physician after a field sting, and c) temporary loss of
consciousness registered by the patient, by bystanders or by an
emergency physician after a field sting (assuming that low blood
pressure leads to unconsciousness). In the absence of hemody-
namic shock, itching/urticaria or flush, we considered dizziness or
light-headedness an uncertain reaction. Corresponding patients
were excluded from the analysis. If a patient had already
experienced systemic symptoms of any kind, and had subsequently
taken anti-allergic drugs, s/he was counted among those in whom
VIT had failed, and was not counted among patients who had
prophylactically taken anti-allergic drugs.
Patients, who exclusively reported shortness of breath, cough-
ing, or anxiety reactions, and who had recovered without taking
any emergency medication, were thought to have tolerated the
venom. Reason for the latter was the finding that, in patients
allergic to Hymenoptera venom, a self-limiting systemic allergic
reaction which is exclusively confined to respiratory symptoms is
an extraordinarily rare event. In honey bee/wasp venom allergy,
exclusive and self-limiting respiratory symptoms rather result from
an unspecific psycho-vegetative reaction [17].
Statistics
Categorical variables were expressed as percentage, metric
variables as median and interquartile range. Selective Compari-
sons between patient groups were made by Fisher’s exact test for
binary variables.
To estimate smooth (non-linear) effects of metric variables, we
used penalized regression splines. Smoothing parameters were
selected by the generalized cross validation criterion. Because of
low data density, we penalized the effect of binary covariates [18].
Covariate-adjusted effects of baseline tryptase concentration
(BTC) on the effectiveness of VIT were evaluated by multiple
logistic regression models, which combined separate effects of all
individual confounding variables (generalized additive models
(GAMs), [19]). GAMs were estimated using an R package [20].
For the dependent variable we used the best subset selection
method to identify a separate starting model which did not include
the variable BTC [8]. A random effect, however, was included to
adjust for study centre. Model performance was assessed using
areas under the curve (AUCs) derived from receiver operating
characteristic (ROC) analyses of the model [21]. To identify the
best model we used a stratified 5-fold cross validation with 5
rounds. To test the tryptase effect, we then added the variable
‘‘baseline tryptase concentration’’ to the starting GAM with the
largest AUC thereby creating the final GAM. Parametric and
semi-parametric effects for tryptase were estimated.
To examine whether the effect of BTC depended on the type of
venom, we used the final GAM to tested interactions between
venom type and BTC. Furthermore, since early prophylactic use
of anti-allergic drugs could have prevented development of
symptoms after a field sting by the culprit insect, we re-estimated
the final GAM using data which did not include corresponding
patients to assess the stability of the estimated effects. We also
constructed another final GAM using only data from patients in
whom VIT effectiveness had been assessed by sting challenge.
Results
Clinical Characteristics of Patients in whom Effectiveness
of VIT could be Assessed
The Tryptase in Hymenoptera Venom Allergy study of the
Interest Group on Insect Venom Hypersensitivity of the EAACI
recently reported outcomes of 680 patients during the build-up
phase of VIT [7]. Effectiveness of VIT could be assessed in 357
patients during the maintenance phase. The majority of patients
were male (59.1%) and were suffering from wasp venom allergy
(74.8%). Median age was 45 years (33–59 years). 32 (9.0%) of the
patients had a BTC .11.4 mg/L (maximum 101.0 mg/L), and 7
(2.0%).20 mg/L. 27.2% of the patients had had a grade III or IV
reaction at the index field sting which preceded immunotherapy.
Effectiveness of Hymenoptera Venom Immunotherapy
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During the build-up or maintenance phase of immunotherapy,
systemic allergic reactions had occurred in 8.4% of the patients.
14 patients (3.9%) had been treated with a maintenance venom
dose of 200 mg. 10 of these patients had been thought to be at a
particularly high risk and had, therefore, received the 200 mg dose.
There were only four patients in whom we had started with a
100 mg dose, and who subsequently were switched to the 200 mg
dose after systemic allergic reactions had occurred during the
maintenance phase of VIT.
No follow up was possible in 323 patients. Compared to the
study group (n= 357 patients), excluded patients were younger
(age 39.5 years (28–51 years), p,0.001) and were less often allergic
to wasp venom (63.2%, p= 0.001). The frequency of male patients
(55.3%, p= 0.321) and of patients presenting with an increased
BTC (.11.4 mg/l) (10.8%, p= 0.795) was, however, comparable.
Of those 323 patients, 303 had to be excluded because of a missing
field sting/sting challenge; in 4 patients there was a significant
uncertainty regarding the stinging insect, 13 were stung be the
presumably wrong insect and 3 patients presented with equivocal
symptoms of their post-sting reaction. Of patients in whom the
identity of the stinging insect was uncertain or not relevant, none
had a systemic allergic reaction after the field sting.
Of patients included into the present study, 154 underwent an
in-hospital sting challenge (43.1%); the remainder of the patients
(n = 203) had a field sting by the culprit insect. Median time
elapsing between the end of build-up and sting challenge/field
sting by culprit insect was 17 months (10–34 months). 14.3% of the
patients took various types of antihypertensive medication at the
time of the sting challenge/field sting. 2.5% of patients were on
beta-blocker therapy, and 4.2% on Angiotensin converting
enzyme (ACE)-inhibitor therapy.
29 patients who were stung by the culprit insect (and who did
not have a sting challenge) used an emergency medication. These
patients exclusively took oral antihistamines or antihistamines and
corticosteroids with intent to prevent allergic reactions. In patients
assessed by self reporting of field sting reactions (n = 203),
preventive use of antihistamines or antihistamines and corticoste-
roids was only observed in a minority of these 203 patients
(14.3%). Of 5 patients who had been stung by the culprit insect
and who simultaneously presented with a BTC .20 mg/L, only
Table 1. Distribution of therapy failures during the maintenance phase of VIT with respect to baseline parameters.
Variable
Emergency intervention (sting challenge)
or generalized symptoms (field sting) p value
No (n=335) Yes (n =22)
Gender male 199 (94%) 12 (6%) 0.407
female 136 (93%) 10 (7%)
Highest degree of index sting reaction preceding VIT I or II 243 (93%) 17 (7%) 0.420
III or IV 92 (95%) 5 (5%)
Type of venom wasp 255 (96%) 12 (4%) 0.027
honey bee 80 (89%) 10 (11%)
Venom dose (mg) during maintenance therapy 100 323 (94%) 20 (6%) 0.211
200 12 (86%) 2 (14%)
Side effects during build-up or maintenance phase yes 26 (87%) 4 (13%) 0.102
no 309 (94%) 18 (6%)
ACE-inhibitor medication at sting challenge/field sting yes 15 (100%) 0 (0%) 0.378
no 320 (94%) 22 (6%)
Beta-blocker medication at sting challenge/field sting yes 9 (100%) 0 (0%) 0.560
no 326 (94%) 22 (6%)
Any antihypertensive medication at sting challenge/field sting yes 39 (98%) 1 (2%) 0.148
no 296 (93%) 21 (7%)
Verification of VIT effectiveness by sting challenge yes 146 (95%) 8 (5%) 0.333
no 189 (93%) 14 (7%)
Preventive use of oral antihistamines or antihistamines
and corticosteroids after the field sting
yes 29 (100%) 0 (0%) 0.145
no 306 (93%) 22 (7%)
Age (years) at sting challenge/field sting according to median ,45 172 (93%) 12 (7%) 0.473
$45 163 (94%) 10 (6%)
Time interval (months) between the end of build up and
sting challenge/field sting according to median
,17 172 (92%) 14 (8%) 0.185
$17 163 (95%) 8 (5%)
BTC (mg/l) according to normal value #11.4 304 (93%) 21 (7%) 0.393
.11.4 31 (93%) 1 (3%)
Associations are shown between clinical, demographic and therapeutic parameters and the need for an emergency intervention during an in-hospital sting challenge
or, after a field sting by the culprit insect, the development of any type of generalized symptom.
doi:10.1371/journal.pone.0063233.t001
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one took oral antihistamines and corticosteroids right after the
sting. None of the 29 patients who prophylactically took anti-
allergic drugs had allergic reactions after a field sting. On the other
hand, generalized reactions developed in 8.1% of the patients (14
of 174 patients) who had not used an emergency kit after a field
sting (p = 0.107). Patient groups using or not using an emergency
medication after a field sting differed slightly: Thus, 20.6% of all
women, but only 11.1% of all men used such medications
(p = 0.089). Parameter values of all other variables were not
significantly different.
In the whole cohort, 22 patients (6.2%) required an emergency
intervention during an in-hospital sting challenge or developed,
after a field sting by the culprit insect, generalized symptoms. This
failure rate is based on the assumption that preventive use of
antihistamines or antihistamines and corticosteroids would have in
fact been unnecessary because of a sufficient protection. However,
we cannot exclude the possibility that a prophylactic anti-allergic
medication was effective in preventing a generalized systemic
reaction which would have been observed without such a therapy.
Assuming such a bias in patients, who had taken antihistamines or
antihistamines and corticosteroids after a sting, the frequency of
VIT failure would be higher maximally amounting to 7.0%.
Risk Factors for VIT Failure
Unadjusted results are presented in Table 1. Without consid-
ering confounders, there was no evidence that the frequency of
VIT failure varied by the venom dose used (100 mg: 5.8%, 200 mg:
14.3%, p= 0.211), or by the method used to assess effectiveness
(failure rates according to self-reporting after a field sting: 6.9%,
according to sting challenge: 5.2%, p= 0.660).
VIT failure was observed more often in patients receiving a
honey bee VIT (11% vs. 4% in patients receiving a vespid VIT).
The difference was even more pronounced in those patients in
whom VIT effectiveness could be assessed by an in-hospital sting
challenge (19% vs. 1%, p,0.001). There was also a tendency for a
lower protection rate in patients, who had had a systemic allergic
reaction during the build up or maintenance phase of VIT (13%
vs. 6%, p= 0.102), whereas preventive use of oral antihistamines
or antihistamines and corticosteroids appeared to reduce the
frequency of generalized symptoms after a field sting (see above).
An increased BTC (.11.4 mg/L) did not increase the frequency of
VIT failure (3% vs. 7% in patients with a BTC #11.4 mg/L,
p = 0.393).
When selecting variables for the starting GAM (which did not
include the variable BTC), a random study centre effect was
retained in the model. Consequently, the final starting model was
adjusted for such an effect. According to AUC values, the best
model was that which included the variables ‘‘therapy with honey
bee venom’’, ‘‘assessment of effectiveness by sting challenge’’,
‘‘ACE-inhibitor medication at sting challenge/field sting’’ and ‘‘
preventive use of oral antihistamines or antihistamines and
corticosteroids after the field sting’’ (AUC=0.7182).
After adjustment for the other confounders, we did not observe
a significant association between BTC and the risk for VIT failure
(Figure 1). Irrespective from the type of effect examined (smooth or
linear), incorporation of BTC also did not increase the AUC of the
starting model (Figure 2). The width of the confidence bands
(Figure 1), however, allowed us to rule out major effects of BTC
(e.g., in comparison to a reference patient with a BTC of 4.3 mg/L
(the sample mean), the odds ratio for a patient with a BTC of
20 mg/L is unlikely to be higher than 2.7).
Inclusion of the variable BTC into the starting model did not
appreciably change the importance of other confounders (Table 2).
Thus, a therapy with honey bee venom remained a potential
predictor for VIT failure, whereas use of an emergency medication
after the field sting, and assessment of effectiveness by sting
challenge presumably had lowered this risk. The latter finding is
remarkable, since in the unadjusted analysis we could not find an
Figure 1. Receiver operating characteristic (ROC) curve for the
final multiple logistic regression model predicting the risk to
need an emergency intervention during sting challenge or to
develop generalized symptoms after a field sting. Models were
tested without including the effect of BTC, or with including a
smoothed or a linear effect. Corresponding areas under the curve were
0.7449, 0.7084 or 0.7240.
doi:10.1371/journal.pone.0063233.g001
Figure 2. Smooth function and pointwise 95% confidence
bands (dashed lines) for the effect of baseline tryptase
concentration on the risk to need an emergency intervention
during sting challenge or to develop generalized symptoms
after a field sting (final multivariate generalized additive
model). Odds ratios are referred to those of the median of tryptase
concentration. The odds ratio of the latter has been set at 1.
doi:10.1371/journal.pone.0063233.g002
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association between the type of effectiveness assessment and VIT
failure emphasizing the importance of considering other con-
founders when estimating the predictive power of an individual
parameter. The comparably small number of patients in whom
treatment failed, however, prevented the identification of clearly
significant effects (p-values between 0.05 and 0.1).
The variable ‘‘ACE-inhibitor medication at sting challenge/
field sting’’ was also retained in the final model. However, the
precise importance of this variable for risk prediction remains
unknown, because of the large uncertainty associated with its
estimated effect. Finally, several other variables were not selected
for the final model by the AUC based algorithm indicating the
prognostic unimportance of age, gender, venom dose during
maintenance therapy, other types of antihypertensive medication,
frequency of systemic allergic reactions during the build-up or
maintenance phase of VIT, severity of the most severe sting
reaction prior to VIT, and duration of VIT.
There was also no evidence that the effect of BTC varied
between wasp and honey bee VIT. After including interactions
between venom type and BTC into an extended model, the
specific association between venom type and BTC was not
significant (p.0.5). Furthermore, incorporation of different types
of BTC effects (linear or smooth) did not increase the AUC of the
extended model.
Since we found evidence that preventive use of antihistamines
or antihistamines and corticosteroids might have prevented
subsequent allergic reactions (thereby possibly obscuring the
assessment of VIT effectiveness), the statistical analysis was
repeated after exclusion of patients having used this self-
medication. Corresponding models and odds ratios, however,
remained virtually unchanged.
Since results obtained by self-reporting of field sting reactions
might be biased, and since we found evidence that verification of
VIT effectiveness depends on the method used, we performed an
additional statistical analysis using only data from patients who
had a sting challenge to assess VIT effectiveness. In that subgroup
analysis, estimation of the variable ‘‘therapy with honey bee
venom’’ yielded an odds ratio of 28.1 (95% confidence interval
3.65–217, p = 0.001), and estimation of the variable ‘‘BTC’’ an
odds ratio of 2.18 (after a logarithmic transformation; 95%
confidence interval 0.68–7.10, p = 0.183). These estimates were
much more pronounced than those based on the full data set.
Discussion
Our study is the largest to evaluate the importance of BTC in
the serum and of a variety of other suspected risk factors for
treatment failure during the maintenance phase of VIT. In our
study, VIT failure was either defined as an objective generalized
symptom during an in-hospital sting challenge or as a systemic
reaction after a field sting by the culprit insect. We found that the
rate of VIT failure may vary between 6.2% and 7.0% (if it is
assumed that a systemic allergic reaction would have occurred in
all patients who had taken preventive anti-allergic drugs).
The effectiveness of VIT is beyond doubt. Two systematic
reviews [22,23] and one meta-analysis [24] have concluded that
VIT is effective in preventing future systemic reactions to venom
in patients with hymenoptera venom allergy. The magnitude of
the effect, however, is highly controversial. According to numerous
randomized, quasi experimental or non-comparative studies, the
reported rates of VIT failure range between 0 and 36% [25]. The
quality of these studies is mostly poor due to small sample size, and
all studies are single centre studies reflecting the experience of a
single institution thereby preventing a generalization of the results.
Furthermore, there is substantial heterogeneity in terms of
differences in venom extracts and concentrations, differences in
administration methods (updosing and/or maintenance programs,
type and length of treatment), differences in the type of
effectiveness assessment, in timing of re-stings and in the
proportion of patients being re-stung. Hockenhull et al [25]
recently pooled data from nine randomized and non-randomized
studies which had used PharmalgenH for VIT. In these studies,
VIT effectiveness had either been assessed by sting provocation or
by accidental field stings. Furthermore, there was no evidence that
field sting reactions could have been obscured by an anti allergic
emergency pre-treatment. The authors found a rate of VIT failure
of 6.5% (22 systemic reactions in 337 patients). This rate
corresponds closely to our findings and suggests that, in unselected
patients and despite the above limitations, the effectiveness of VIT
is excellent and highly reproducible.
The key finding of our study is that there was no strong
association between BTC and the frequency of treatment failure
during the maintenance phase of VIT. Due to the width of the
confidence bands, however, smaller effects of BTC cannot be
excluded. It has recently been speculated that there might be
negative effects of an elevated BTC/mastocytosis on the success
rate of VIT [10]. A systematic review pooled data from seven
observational studies examining VIT effectiveness in mastocytosis.
The authors found that 28% of the treated patients (23 of 82
patients) had a systemic reaction to a re-sting [10]. This failure rate
is almost five times higher than the average failure rate of 6%
found in unselected cohorts (including the one in the present
study). According to our data, however, the magnitude of the
BTC/mastocytosis effect might have been overestimated in that
analysis, which could not adjust results to potential confounders.
The size of our cohort would have been sufficient to detect a
more than 4-fold increase of the rate of VIT failure due to an
elevated BTC (.11.4 mg/l). Assuming that about 10% of patients
present with an increased BTC (.11.4 mg/l), and assuming
Table 2. Results of the final generalized additive model for the risk to need an emergency intervention during an in-hospital sting
challenge or, after a field sting by the culprit insect, to develop any type of generalized symptom.
Variable p value odds ratio 95% confidence interval
Therapy with honey bee venom 0.100 2.209 0.860 5.675
Verification of VIT effectiveness by sting challenge 0.070 0.344 0.109 1.091
ACE-inhibitor medication 0.495 0.461 0.050 4.265
Preventive use of oral antihistamines or antihistamines and corticosteroids after the field sting 0.101 0.203 0.030 1.362
Those variables are shown, which were selected according to the modeling procedure. P-values and widths of confidence intervals are biased downwards due to the
effect of subset selection.
doi:10.1371/journal.pone.0063233.t002
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further that the probability of VIT failure is about 5% for patients,
who have a normal BTC, it may be calculated that a study would
have to analyse at least 331 patients to detect such an increase in
frequency (two-sided type I error, 5 percent; power, 80 percent).
Our data provide some evidence, however, that weaker effects of
BTC might indeed exist. A subgroup analysis in patients in whom
we had used sting challenge to asses VIT effectiveness revealed
such a weak BTC effect (OR 2.18 for a 2.7 fold increase of BTC)
which was retained in the final statistical model and which, for
reasons discussed below, might be more reliable than the effect
estimated for the whole cohort. Consequently, our findings suggest
that a minority of patients (presumably those presenting with a
particularly high BTC) may not benefit from a standard VIT to
the same extent as patients with a normal BTC.
Several other conclusions may be derived from our results. In
accordance with numerous other studies, bee venom allergy was
an independent predictor for VIT failure. A systematic review
found that only 0–9% of patients allergic to wasp venom, but
about 20% of bee venom allergic patients still reacted to a sting
challenge with the culprit insect [11]. It is also established that
immunotherapy with bee venom is a major risk factor for severe
side effects during the build-up phase of VIT [7,11]. On the other
hand, we and others have shown that, before VIT, honey bee
venom allergy is an important predictor for a lower risk of a severe
systemic reaction after a field sting [1,26,27]. Consequently, the
worse results associated with honey bee venom immunotherapy
must be attributed to the treatment itself. Thus far, it is entirely
unclear why a treatment with honey bee venom is associated with
a higher rate of side effects and treatment failures. We have
recently speculated that this phenomenon relates to the amount of
venom dose applied during therapy. In honey bee and wasp VIT
the total number of therapeutic injections is the same. In
comparison to wasp VIT and to the amount of wasp venom
emitted during a field sting, patients receiving a honey bee venom
immunotherapy are, however, exposed to a significantly greater
number of injections, which provide subclinical amounts of venom
thereby possibly favouring pro-allergic reactions during therapy,
and treatment failures [7]. Conversely, it is also possible that wasp
VIT is more effective than bee VIT because there are marked
differences in the amount of venom emitted during a field sting
(honey bee: 50 to 100 mg; wasp: 3 to 5 mg), whereas the amount of
venom applied during the maintenance phase of VIT is identical.
Therefore, compared to field sting conditions, patients allergic to
wasp venom receive a much greater dose possibly resulting in a
better protection.
Another interesting finding of our study was that the method
which had been used to assess effectiveness correlated with the
chance of VIT failure. VIT seemed to be less effective when
evaluated by patient self-reporting (systemic allergic reactions after
a field sting) than when evaluated by in-hospital sting challenge.
Thus, the adjusted frequency of systemic allergic reactions was
lower during sting challenge than after a field sting. Differences
between those two methods used to provoke an allergic reaction
are well established and have been demonstrated again recently by
studies assessing the effectiveness of VIT in patients with
mastocytosis [10,13].
To explain these divergent results two different hypotheses have
been put forward. The first assumes that the risk for severe allergic
reactions is greater during normal life than when being
deliberately tested in well-prepared patients in a highly artificial
environment excluding those who have contraindications for sting
challenge [13]. In such a setting this bias would artificially reduce
the frequency of VIT failures. The second hypothesis focuses on
the historical assessment of preceding symptoms. Within such a
procedure a bias may exist affecting the reliability of information
obtained by self-reporting after a field sting. There are numerous
misconceptions related to a patient’s comprehension, recall,
evaluation and expression [28,29]. Despite VIT, a new sting
may be preconceived by the patient as a risk factor of future severe
allergic reactions making him inflate the importance of post-sting
symptoms. Thus, subjective symptoms after a field sting can be
described as severe by patients but can be viewed as subjective and
not significant during sting challenge. Such a mechanism would
artificially increase the frequency of VIT failures after a field sting.
The relative importance of those two hypothesis is unknown but
allergists tend to favour the second one [30].
Three other aspects of our results deserve a specific comment.
When analyzing the use of self medication after a field sting by the
culprit insect, we found an association with the rate of VIT failure
(Table 2). Although significance was marginal, this effect was
retained in the final statistical model emphasizing the prognostic
importance of this variable. Preventive use of oral antihistamines
or antihistamines and corticosteroids appeared to decrease the risk
of a systemic allergic reaction thereby supporting corresponding
guideline and practice parameter recommendations [8,11,31]. It
should be noted, however, that this finding is also subject to a
recall bias. Patients feeling reassured by self-medication might
have been less likely to report symptoms.
Only about 14% of the patients used oral antihistamines or
antihistamines and corticosteroids to prevent allergic reactions
after a field sting. This finding precisely corresponds to the
depressingly low frequency (about 14%) with which oral antial-
lergic drugs are taken after unselected severe allergic reactions in
the community of German speaking countries [32]. These low
frequencies reveal an extraordinarily poor patient compliance and
underscore the need for an intensified patient education and
training.
Finally, we found no evidence that side effects during the build-
up or maintenance phase correlated with treatment effectiveness.
During VIT, the strongest predictor for severe side effects is a
therapy with honey bee venom [7]. Since the latter variable is also
associated with the chance of VIT failure, it is likely that the
importance of the type of venom for treatment success outweighed
the importance of side effects during VIT.
There was also no association between the duration of VIT and
the frequency of VIT failure. It is commonly believed that the
length of VIT correlates with the protection rate. A recent study,
however, suggested that in the majority of allergic patients VIT is
effective within a week after the maintenance dose has been
achieved [33]. In most of the patients in our study, however, the
effectiveness of VIT could be only assessed between months 10
and 34 of maintenance therapy. It appears that at least during this
time span the protection rate largely remains unchanged.
Strengths and Limitations of the Study
The major strength of this study is the large number of patients,
and the prospective und multicentre design allowing a general-
ization of obtained findings. The study, however, is also subject to
several limitations. Only about half of the original patient cohort
which had had a VIT [7] was evaluable in terms of effectiveness
assessment (either by sting challenge or self reporting of outcomes
after a field sting). This might represent a selection bias,
particularly in view of the fact that, compared to patients in the
present study, excluded patients differed in terms of age and
frequency of bee/wasp venom allergy. Furthermore, self reporting
implies errors concerning the correct identification of the insect
involved in a field sting, the correct reporting of symptoms, and
the true amount of venom delivered by the sting. In addition, the
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small number of events (VIT failures) prevented a thorough
analysis of BTC and of a variety of other variables possibly
important for the protection rate. Finally, it is also possible that a
portion of the absent effect of BTC was due to an analytical error.
A certain, albeit small number of patients might have presented
with heterophilic antibodies which may falsely increase BTC
[34,35].
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